Amgen Inc. (NASDAQ:AMGN) Shares Sold by Measured Wealth Private Client Group LLC

Measured Wealth Private Client Group LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 25.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 901 shares of the medical research company’s stock after selling 314 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Amgen were worth $290,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Strategic Financial Concepts LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at about $26,000. Hershey Financial Advisers LLC acquired a new stake in Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC bought a new position in Amgen during the 2nd quarter worth approximately $31,000. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter worth approximately $33,000. Finally, Matrix Trust Co bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 1.0 %

Shares of Amgen stock opened at $318.83 on Thursday. The business has a fifty day simple moving average of $324.75 and a 200-day simple moving average of $314.78. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The firm has a market cap of $171.03 billion, a price-to-earnings ratio of 45.08, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter last year, the firm posted $4.96 EPS. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.82%. Amgen’s dividend payout ratio is currently 128.57%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Bank of America lifted their price objective on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and raised their target price for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Sanford C. Bernstein started coverage on Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective for the company. Finally, TD Cowen upped their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $332.55.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.